Compare Eli Lilly And Co (LLY) vs AT&T Inc. (T) Price & Performance

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

AT&T (T) trades at $21.91, up 0.52% today, with a bullish technical signal and strong fundamentals including a 17.47% net income margin and consistent earnings beats. The stock shows improving cash flow trends, with net cash flow turning positive to $15.12B in 2025. Recent news highlights fiber expansion and competitive threats from Starlink, while analyst consensus leans toward a buy with a $26.18 price target.

The outlook is cautiously optimistic given attractive valuation multiples like a P/E of 7.34 and a 19.95% ROE, but risks include intense telecom competition and debt levels. The stock offers a dividend yield supported by sustainable cash flows, positioning it as a value play with moderate growth potential amid industry headwinds.